RESUMEN
This review summarizes data on the effectiveness of lercanidipine. Lercanidipine is dihydropyridine calcium antagonist of the third generation, characterized by high vazoselective, long duration of action and good antihypertensive effect. It may be assigned to elderly patients with isolated hypertension and has several important organoprotective properties. Treatment with lercanidipine promotes nephroprotection, reduction of left ventricular hypertrophy, improvement of elastic properties of blood vessels and reduction of central pressure. Sympathetic activation in the application of lercanidipine is virtually absent, that ensures its good tolerability and high adherence of patients to treatment.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Bloqueadores de los Canales de Calcio/uso terapéutico , Dihidropiridinas/uso terapéutico , Hipertensión/tratamiento farmacológico , Humanos , Hipertensión/fisiopatología , Resultado del TratamientoRESUMEN
Results of the investigation of metoprolol CR/XL which was conducted in large randomized controlled study MERIT-HF in patients with chronic heart failure (CHF) are presented. In the whole trial this beta1-selective blocker lowered mortality of patients with CHF. Analysis of results in subgroups shows that metoprolol CR/XL was equally effective in middle aged and old patients, in men and women.
Asunto(s)
Antagonistas Adrenérgicos beta/administración & dosificación , Insuficiencia Cardíaca/tratamiento farmacológico , Metoprolol/análogos & derivados , Preparaciones de Acción Retardada , Relación Dosis-Respuesta a Droga , Insuficiencia Cardíaca/mortalidad , Insuficiencia Cardíaca/fisiopatología , Humanos , Metoprolol/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Tasa de Supervivencia/tendencias , Resultado del Tratamiento , Función Ventricular IzquierdaRESUMEN
Results of drug treatment of 51 patients (41 men, 10 women) aged 35-86 years (mean age 62 years) included into COPERNICUS trial are presented. All patients had compensated NYHA class IV chronic heart failure and left ventricular ejection fraction less than 25%. For at least 2 months the patients received therapy with diuretics and angiotensin converting enzyme inhibitors (84%) or angiotensin receptor blockers (16%) and then were randomized to either carvedilol or placebo. Average duration of follow-up was 17 months. Carvedilol was well tolerated both during dose titration and during maintenance therapy. Addition of carvedilol to standard therapy of patients with severe heart failure was associated with increase of average ejection fraction from 21.7 to 30.3%. Rates of cardiovascular and sudden deaths, risk of hospitalization among carvedilol treated patients were 25, 33 and 57% less than among patients subjected only to standard therapy.
